FDAnews Device Daily Bulletin

MicroTransponder Closes $5.5 Million in Financing

Dec. 11, 2015

Dallas, Texas-based MicroTransponder has secured $5.5 million in funding to commercialize its stroke and tinnitus therapy in Europe in 2016, as well as to complete additional clinical studies.

The company’s Vivistim device aims to treat stroke patients with upper limb deficit following a stroke.  It is equipped with a small implanted battery and wires that internally connect to the vagus nerve in the neck.

Patients receive a small amount of neurostimulation to the nerve during rehabilitation to strengthen neural pathways in the brain.

The financing was led by Green Park & Golf Ventures. — Michael Cipriano